Literature DB >> 16311411

Pituitary tumors: prognostic indicators.

Wolfgang Saeger1.   

Abstract

Many factors influence the proliferation of pituitary adenomas: angiogenesis, apoptosis, growth factors, oncogenes, tumor suppressor genes, and hormone receptors. These elements can be demonstrated by immunohistochemistry and/or molecular pathology but no single factor can be used for determination of biological behavior resp. prognosis. Pituitary adenomas can be enclosed or invasive and may be very large or may be microadenomas, but the most important point for prognosis is the total resection in the first or second surgery or the reaction on treatments by drugs. Especially for residual tumor tissue proliferation, markers are important because they may indicate the growth rate and the aggressiveness of the tumor. Radiation therapy is indicated in many of these recurrent tumors and can improve the prognosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16311411     DOI: 10.1385/ENDO:28:1:057

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  75 in total

1.  [Guidelines for radiotherapy of pituitary adenomas. German Society of Endocrinology].

Authors:  R Engenhart-Cabillic; M Kocher; R P Müller; J Voges; V Sturm; F Jockenhövel; R Fahlbusch; M Mokry; H J Quabbe
Journal:  Dtsch Med Wochenschr       Date:  1999-10-01       Impact factor: 0.628

Review 2.  Medical management of prolactin-secreting pituitary adenomas.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

3.  Frequent loss of the P16INK4a gene product in human pituitary tumors.

Authors:  M Woloschak; A Yu; J Xiao; K D Post
Journal:  Cancer Res       Date:  1996-06-01       Impact factor: 12.701

4.  The c-erbB-2/neu proto-oncogene in human pituitary tumours.

Authors:  S Ezzat; L Zheng; H S Smyth; S L Asa
Journal:  Clin Endocrinol (Oxf)       Date:  1997-05       Impact factor: 3.478

5.  GH-, PRL-, POMC-, beta-TSH-, beta-LH-, beta-FSH-mRNA in gonadotroph adenomas of the pituitary by in situ hybridization in comparison with immunostaining and clinical data.

Authors:  A Münscher; M Schmid; W Saeger; S Schreiber; D K Lüdecke
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

6.  Topoisomerase IIalpha expression in pituitary adenomas and carcinomas: relationship to tumor behavior.

Authors:  Sergio Vidal; Kalman Kovacs; Eva Horvath; Fabio Rotondo; Takao Kuroki; Ricardo V Lloyd; Bernd W Scheithauer
Journal:  Mod Pathol       Date:  2002-11       Impact factor: 7.842

Review 7.  Molecular pathogenesis of pituitary tumors.

Authors:  W E Farrell; R N Clayton
Journal:  Front Neuroendocrinol       Date:  2000-07       Impact factor: 8.606

8.  The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas.

Authors:  Giuseppe Minniti; Marie-Lise Jaffrain-Rea; Mattia Osti; Vincenzo Esposito; Antonio Santoro; Francesca Solda; Patrizia Gargiulo; Guido Tamburrano; Riccardo Maurizi Enrici
Journal:  Clin Endocrinol (Oxf)       Date:  2005-02       Impact factor: 3.478

9.  Prepubescent pituitary null cell macroadenoma with silent macroscopic apoplexy: case report.

Authors:  T Mizutani; A Teramoto; T Aruga; K Takakura; N Sanno
Journal:  Neurosurgery       Date:  1993-11       Impact factor: 4.654

10.  Treatment of acromegaly with the long-acting somatostatin analog SMS 201-995.

Authors:  A L Barkan; R P Kelch; N J Hopwood; I Z Beitins
Journal:  J Clin Endocrinol Metab       Date:  1988-01       Impact factor: 5.958

View more
  8 in total

1.  The clinical significance of MIB-1 labeling index in pituitary adenomas.

Authors:  Geeta Chacko; Ari G Chacko; Kalman Kovacs; Bernd W Scheithauer; Sunithi Mani; J P Muliyil; M S Seshadri
Journal:  Pituitary       Date:  2010-12       Impact factor: 4.107

2.  Predictive value of PWI for blood supply and T1-spin echo MRI for consistency of pituitary adenoma.

Authors:  Zengyi Ma; Wenqiang He; Yao Zhao; Jie Yuan; Qilin Zhang; Yue Wu; Hong Chen; Zhenwei Yao; Shiqi Li; Yongfei Wang
Journal:  Neuroradiology       Date:  2015-09-16       Impact factor: 2.804

Review 3.  Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma).

Authors:  Nèle Lenders; Ann McCormack
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

4.  Nomogram predictive model of post-operative recurrence in non-functioning pituitary adenoma.

Authors:  Wen Lyu; Xu Fei; Cheng Chen; Yuqun Tang
Journal:  Gland Surg       Date:  2021-02

Review 5.  Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis.

Authors:  Ferdinand Roelfsema; Nienke R Biermasz; Alberto M Pereira
Journal:  Pituitary       Date:  2012-03       Impact factor: 4.107

6.  5-ALA Fluorescence in Native Pituitary Adenoma Cell Lines: Resection Control and Basis for Photodynamic Therapy (PDT)?

Authors:  Andrei Nemes; Thomas Fortmann; Stephan Poeschke; Burkhard Greve; Daniel Prevedello; Antonio Santacroce; Walter Stummer; Volker Senner; Christian Ewelt
Journal:  PLoS One       Date:  2016-09-01       Impact factor: 3.240

7.  Histological criteria for atypical pituitary adenomas - data from the German pituitary adenoma registry suggests modifications.

Authors:  Christian P Miermeister; Stephan Petersenn; Michael Buchfelder; Rudolf Fahlbusch; Dieter K Lüdecke; Annett Hölsken; Markus Bergmann; Hans Ulrich Knappe; Volkmar H Hans; Jörg Flitsch; Wolfgang Saeger; Rolf Buslei
Journal:  Acta Neuropathol Commun       Date:  2015-08-19       Impact factor: 7.801

8.  Clinical Concerns about Recurrence of Non-Functioning Pituitary Adenoma.

Authors:  Min Ho Lee; Ju Hee Lee; Ho Jun Seol; Jung-Il Lee; Jong Hyun Kim; Doo-Sik Kong; Do-Hyun Nam
Journal:  Brain Tumor Res Treat       Date:  2016-04-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.